Ben Eloff has been on the forefront of medical innovation for his entire 19-year federal career, which he now applies to help innovators navigate the complex pathways to bring new medical products to patients. From approving the first ablation therapy for atrial fibrillation by using the first adaptive Bayesian trial design in medical devices to leading the publication of the first FDA guidance on the use of real-world evidence, he has consistently looked for ways to generate the best scientific evidence with the least burden in service of public health. Dr. Eloff has championed the power of public-private partnerships through his pioneering work to establish the Cardiac Safety Research Consortium, Medical Device Epidemiology Network, and KidneyX Innovation Accelerator, among many others. These partnerships bring together experts from medical product developers, patients, physicians, academics, and federal agencies to address scientific questions and accelerate new technologies to the people who need them. Dr. Eloff awarded and managed over $50 million in federal contracts, grants, and prize competitions to support innovation. Dr. Eloff served as the Director of Innovation Management in the Office of the Assistant Secretary for Health. At FDA, he served as Deputy Director of the Division of Epidemiology, and lead premarket reviewer in the Center for Devices and Radiological Health, and Senior Scientific Program Manager for Public-Private Partnerships in the Office of Chief Scientist. Dr. Eloff earned his MS (2001) and PhD (2005) in Biomedical Engineering and BS (1998) in Electrical Engineering from Case Western Reserve University in Cleveland, Ohio. Ben is also a proud Eagle Scout and continues service in his community supporting Scouting, music, and suicide prevention.